2024
Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors
Kwan J, Shen M, Akhlaghi N, Hu J, Mora R, Cross J, Jiang M, Mankbadi M, Wang P, Zaman S, Lee S, Im Y, Feher A, Liu Y, S. S, Tao W, Wei W, Baldassarre L. Adverse cardiovascular events and cardiac imaging findings in patients on immune checkpoint inhibitors. PLOS ONE 2024, 19: e0314555. PMID: 39621799, PMCID: PMC11611253, DOI: 10.1371/journal.pone.0314555.Peer-Reviewed Original ResearchConceptsAdverse cardiovascular eventsICI therapyCardiac magnetic resonanceIncreased risk of mortalityICI initiationIncreased riskRisk of mortalityCentral nervous systemVentricular dysfunctionCancer patients treated with ICIsCardiovascular eventsLeft ventricular late gadolinium enhancementMortality benefitCardiovascular riskAbnormal left ventricular ejection fractionPatients treated with ICIsLeft ventricular ejection fractionCentral nervous system malignanciesRisk of adverse cardiovascular eventsImmune checkpoint inhibitorsRight ventricular dysfunctionGlobal longitudinal strainVentricular ejection fractionLeft ventricular dysfunctionMultimodality cardiac imagingrBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors
Wang X, Wei W. rBMA: A robust Bayesian Model Averaging Method for phase II basket trials based on informative mixture priors. Contemporary Clinical Trials 2024, 140: 107505. PMID: 38521384, PMCID: PMC11849277, DOI: 10.1016/j.cct.2024.107505.Peer-Reviewed Original ResearchConceptsPhase II basket trialRobust Bayesian modelBasket trial designBiomarker-defined subgroupsMixture priorsBinary endpointsModel averaging methodPosterior distributionBayesian modelBasket trialsSimulation studyEra of targeted therapyDevelopment of targeted agentsPriorsAverage methodGenomic alterationsPatient populationNovel treatmentAntitumor activityPosterior weightsEarly phase oncology trialsStatistical powerOncology trialsTrial designTrials
2023
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
Cecchini M, Walther Z, Wei W, Hafez N, Pilat M, Boerner S, Durecki D, Eder J, Schalper K, Chen A, LoRusso P. NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) Plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors. Cancer Research Communications 2023, 3: 1113-1117. PMID: 37377610, PMCID: PMC10292219, DOI: 10.1158/2767-9764.crc-22-0485.Peer-Reviewed Original ResearchConceptsDose-limiting toxicityHomologous recombination deficiencyPARP inhibitorsStable diseaseWeekly irinotecanObjective responseDay 1Day 3Solid tumorsPhase I dose-escalation studyTwice daily days 1I dose-escalation studyPhase I clinical trialDaily days 1Dose level 1Doses of veliparibGrade 3 neutropeniaMultiple-dose schedulesProgression-free survivalAdvanced solid tumorsDose-escalation studyEvaluable patientsNonoverlapping toxicitiesDose scheduleSystemic treatment
2021
Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade
Peters GW, Tao W, Wei W, Miccio JA, Jethwa KR, Cecchini M, Johung KL. Publication Bias in Gastrointestinal Oncology Trials Performed over the Past Decade. The Oncologist 2021, 26: 660-667. PMID: 33728733, PMCID: PMC8342580, DOI: 10.1002/onco.13759.Peer-Reviewed Original ResearchConceptsGI oncologyPublication biasImpact of RCTsFuture trial designMultivariable logistic regressionSignificant publication biasPast trialsAccrual completionCancer RCTsEvidence-based practiceGastrointestinal cancerClinical managementTrial completionTrial designOncology trialsClinical practicePublication statusRCTsTrial questionModern RCTsLogistic regressionHalf of trialsTrialsPhase IIIGold standard
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply